Harpoon Therapeutics raises $70M Series C for T-cell engager therapies
The company is currently running a Phase I study in prostate cancer and plans to advance additional therapies into Phase I trials and IND-enabling studies next year.
Taiho Pharmaceutical’s venture capital arm gets sixfold funding increase
Taiho Ventures' investment pool is increased by $250 million, to $300 million. The fund will primarily focus on drugs for treating cancers.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.